A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed

被引：0
|
作者：
Halabi, Susan
Lin, Chen-Yen
Small, Eric Jay
Armstrong, Andrew J.
Kaplan, Ellen B.
Petrylak, Daniel Peter
Sternberg, Cora N.
Shen, Liji
Oudard, Stephane
De Bono, Johann Sebastian
Sartor, A. Oliver
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Duke Univ, Durham, NC USA
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[4] Duke Univ, Div Med Oncol & Urol, Duke Canc Inst, Durham, NC USA
[5] Duke Univ, Div Med Oncol & Urol, Duke Prostate Ctr, Durham, NC USA
[6] Yale Univ, Smilow Canc Hosp, New Haven, CT USA
[7] San Camillo & Forlanini Hosp, Rome, Italy
[8] Sanofi, Malvern, PA USA
[9] Hop Europeen Georges Pompidou, Paris, France
[10] Inst Canc Res, London SW3 6JB, England
[11] Tulane Canc Ctr, New Orleans, LA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.24
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
24
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC)
    Halabi, S.
    Kelly, W. K.
    George, D. J.
    Morris, M. J.
    Kaplan, E. B.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [2] A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy
    Halabi, Susan
    Lin, Chen-Yen
    Small, Eric Jay
    Armstrong, Andrew J.
    Kaplan, Ellen B.
    Petrylak, Daniel Peter
    Sternberg, Cora N.
    Shen, Liji
    Oudard, Stephane
    De Bono, Johann Sebastian
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer
    Halabi, S.
    Lin, C. Y.
    Kelly, W. K.
    Fizazi, K.
    Moul, J. W.
    Kaplan, E.
    Morris, M. J.
    Small, E. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S679 - S679
  • [4] Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy
    Halabi, Susan
    Armstrong, Andrew J.
    Sartor, A. Oliver
    De Bono, Johann Sebastian
    Kaplan, Ellen B.
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Overall survival beyond first-line docetaxel in patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
    Heo, Mi Hwa
    Park, Se Hoon
    Kim, Hee Kyung
    Cho, Jinhyun
    Kim, Youjin
    Lee, Hansang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
    Halabi, Susan
    Lin, Chen-Yen
    Kelly, W. Kevin
    Fizazi, Karim S.
    Moul, Judd W.
    Kaplan, Ellen B.
    Morris, Michael J.
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (07) : 671 - +
  • [7] MITOXANTRONE AS SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER (CRPC)
    Morales, R.
    Valverde, C.
    Suarez, C.
    Brana, I.
    Planas, J.
    Padros, O.
    Maldonado, X.
    Morote, J.
    Carles, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 301 - 301
  • [8] Survival benefits of second-line chemotherapy in metastatic castrate-resistant prostate cancer (CRPC) in a southeastern oncology community practice.
    Gilmore, James W.
    Haislip, Sally
    Szabo, Stephen
    Sullivan, Sean D.
    Ramsey, Scott David
    Kreilick, Charles
    Boklage, Susan H. Foltz
    Sarma, Syam
    Asche, Carl V.
    Shermock, Kenneth M.
    Sun, Kai
    Valluri, Satish
    Seal, Brian S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone
    Ravi, Praful
    Mateo, Joaquin
    Lorente, David
    Zafeiriou, Zafeiris
    Altavilla, Amelia
    Ferraldeschi, Roberta
    Sideris, Spyridon
    Grist, Emily
    Smith, Alan
    Wong, Sophia
    Bianchini, Diletta
    Attard, Gerhardt
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2014, 66 (01) : 8 - 11
  • [10] Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer (mCRPC).
    Marar, Mallika
    Long Qi
    Mamtani, Ronac
    Narayan, Vivek
    Vapiwala, Neha
    Parikh, Ravi Bharat
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345